Biomarkers for the Detection of Cancer and Monitoring Response to Treatment

Dear Colleagues,

This Special Issue on biomarkers in cancer focusses on the latest advancements and applications of biomarkers, in all of their forms, that can facilitate the detection, inform best practice treatment, and monitor responses. The scope of this Special Issue includes their discovery, validation, and clinical implementation. We hope to promote the advancement of cancer biomarker research through the dissemination of the latest cancer biomarker research, facilitating the translation of laboratory finding into clinical tools and, ultimately, improved patient outcomes.

Other literature exists on biomarker research across cancer, but sits side-by-side with biology and clinical therapy trials; here. we focus on the key role that cancer biomarkers can play in developing precision medicine and personalised approaches.

We aim to provide a platform for researchers to share their findings and foster collaboration and an outlet for the description of new and emerging biomarkers, including those related to the tumour microenvironment, immune response, and genetic alterations. To examine methodologies and challenges associated with validating biomarker performance and ensuring their reliability, we are investigating the utility of biomarkers in clinical settings and how biomarkers are driving individualised treatment plans and targeted therapy for difference cancer subtypes. Finally, we want to highlight the latest developments in biomarker detection, analysis, and sample preparation.

We hope that this Special Issue will provide a comprehensive resource for scientists, clinicians, and anyone interested in the latest advancements in cancer biomarkers, with the aim of advancing cancer treatment and improving patient care through targeted personalised treatments.

Dr. Barbara Guinn
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Onco is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.